Testicular Cancer Treatment Regimens
Get the latest treatment regimens for testicular cancer, including options such as carboplatin, EP + cisplatin, BEP, and VIP.
Diagnosis & Disease Information
Prostate Cancer Treatment Regimens
Find detailed treatment options for prostate cancer, including clinical trials and anticancer agents such as docetaxel, prednisone, and sipuleucel-T.
Darolutamide Gets Priority Review for Non-Metastatic Castration-Resistant Prostate Cancer
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for darolutamide (Bayer and Orion), an investigational treatment for non-metastatic castration-resistant prostate cancer (nmCRPC).
Single-Dose Brachytherapy Effective for Prostate Cancer
Two-year and three-year biochemical progression-free survival rate of 100 percent for low-risk disease
Investigational Antiandrogen Drug Delays Metastasis in CRPC
Among men with nonmetastatic castration-resistant prostate cancer, those who were treated with darolutamide had a 59% decreased risk of metastasis compared with placebo recipients.
Abiraterone, Prednisone With Androgen Deprivation Therapy Show Durable Efficacy in Metastatic Castration-Naive Prostate Cancer
At a median follow-up of nearly 52 months, the treatment regimen deceased mortality risk among men with high-risk metastatic castration-naive prostate cancer by 30%.
Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer
After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death.
Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
At 23 years of follow-up, the cumulative incidence of death was higher among patients in the watchful waiting group compared with those in the radical prostatectomy group.
Newer mCRPC Drugs Led to Longer Survival in African American Patients
The study is the first to show that treatment with abiraterone acetate/enzalutamide is associated with better survival in African American patients with mCRPC compared with Caucasians.
Metastatic Prostate Cancer Responds to Novel Radiation Therapy
By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.
- Loading...
Loading...
Next post in Genitourinary Cancers Symposium 2019
Loading... 
Loading...